(Reuters) – Contract drugmaker Emergent BioSolutions Inc on Thursday posted a first-quarter profit compared with a year-ago loss, boosted by robust demand for its services that help produce COVID-19 vaccines.
Net income was $69.7 million, or $1.28 per share, in the first quarter ended March 31 versus a loss of $12.5 million, or 24 cents per share, a year earlier.
Revenue rose to $343 million from $192.5 million.
(Reporting by Trisha Roy in Bengaluru; Editing by Devika Syamnath)
